(VIANEWS) – The NASDAQ opens in less than one hour and Cintas Corporation‘s pre-market value is already 4.21% up. Cintas Corporation’s last close was $633.40, 0.47% below its 52-week high of $636.37. The last session, NASDAQ finished with Cintas Corporation (CTAS) sliding 0.36% to $633.40. NASDAQ slid 0.42% to $16,315.70, after two sequential sessions in…
(VIANEWS) – The NASDAQ opens in less than one hour and Criteo‘s pre-market value is already 4.82% up. Criteo’s last close was $35.07, 0.6% under its 52-week high of $35.28. The last session, NASDAQ finished with Criteo (CRTO) jumping 0.11% to $35.07. NASDAQ dropped 0.42% to $16,315.70, after two consecutive sessions in a row of…
(VIANEWS) – Gevo (NASDAQ: GEVO) shares have experienced an extraordinary decrease of 31.58%, falling 67.55% off its 52-week high of EUR1.88 to close at EUR0.61. Across 21 sessions, shares of Gevo have experienced two consecutive sessions of losses, falling further on Tuesday to close at EUR0.61. In total, the entire NASDAQ market saw its value…
(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session. The three biggest winners today are Viking Therapeutics, Research Frontiers Incorporated, and Canopy Growth. Rank Financial Asset Price Change Updated (EST) 1 Viking Therapeutics (VKTX) 80.83 16.82% 2024-03-26 15:08:03 2 Research…
(VIANEWS) – Sabre Corporation (SABR) shares experienced a sharp 17.26% gain over five sessions from EUR2.03 to EUR2.36 on Tuesday – this came after two consecutive days of losses and following an upward trend in previous sessions. Meanwhile, the NASDAQ index rose 0.25% after experiencing an initial downward trend in previous session; Sabre Corporation closed…
(VIANEWS) – FibroGen (NASDAQ: FGEN) experienced an unprecedented 30.98% surge over the past 21 sessions, rising from EUR1.98 on February 28th to EUR2.59 at 12:57 EST Tuesday at 12:57, marking five straight sessions of gains. Meanwhile, NASDAQ is also showing signs of life with its Index currently up 0.39% at EUR16,447.96; FibroGen’s last close price…
About Viking Therapeutics Viking Therapeutics is a clinical-stage biopharmaceutical company, focused on the creation of innovative treatments for metabolic and endocrine conditions. VK2809, their lead drug candidate, is a tissue and receptor subtype selective agonist of thyroid hormone receptor beta currently in Phase IIb clinical trials for treating nonalcoholic steatohepatitis and nonalcoholic fatty liver disease…
(VIANEWS) – The NYSE opens in less than hour and McCormick & Company‘s pre-market value is already 6.31% up. McCormick & Company’s last close was $69.94, 25.9% below its 52-week high of $94.39. The last session, NYSE ended with McCormick & Company (MKC) sliding 0.13% to $69.94. NYSE fell 0.19% to $18,077.15, after two consecutive…
(VIANEWS) – The NYSE opens in less than hour and AMETEK‘s pre-market value is already 4.43% up. AMETEK’s last close was $182.76, 0.02% above its 52-week high of $182.72. The last session, NYSE finished with AMETEK (AME) sliding 0.21% to $182.76. NYSE slid 0.19% to $18,077.15, after two successive sessions in a row of losses,…
(VIANEWS) – The NASDAQ opens in less than hour and Viking Therapeutics‘s pre-market value is already 14.54% up. Viking Therapeutics’s last close was $69.19, 30.4% under its 52-week high of $99.41. The last session, NASDAQ finished with Viking Therapeutics (VKTX) dropping 0.52% to $69.19. NASDAQ slid 0.27% to $16,384.47, following the last session’s downward trend…
